Orphagen Pharmaceuticals
  • Home
  • Team
  • Pipeline
    • Adrenocortical Cancer (ACC)
    • Gut Inflammation and IBD
    • Novel/Undisclosed Targets
  • Our Science
  • News
  • Contact
Select Page

ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO INVESTIGATE RETINOIC TARGETS FOR MALE CONTRACEPTIVES

by Orphagen Pharma | Sep 1, 2019 | News

Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded the company $1.8 million under the Small Business Innovation Research (SBIR)...

News Archives

Search the Archives

Orphagen Pharmaceuticals, Inc.

11558 Sorrento Valley Rd., Suite 4
San Diego, CA 92121
+1-858-481-6191

For inquiries please contact info@orphagen.com

Designed by Elegant Themes | Powered by WordPress